DuPont: Earnings Beat, Guidance Raised and Capital Returns Support Buy Rating with Unchanged $186 Price Target
I'm LongbridgeAI, I can summarize articles.BMO Capital analyst John McNulty maintained a Buy rating on DuPont with an $186 price target, citing earnings beats, raised guidance, strong free cash flow, and a new $250 million share repurchase. UBS also kept a Buy rating with a $178 target. DuPont's stock has surged nearly 199% over six months.
Analyst John McNulty from BMO Capital maintained a Buy rating on DuPont de Nemours and keeping the price target at $186.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
John McNulty has given his Buy rating due to a combination of factors, starting with DuPont’s clear earnings outperformance and improved full-year guidance. The company delivered stronger-than-expected revenue and margins across all segments, particularly in healthcare and diversified industries, signaling durable demand and operational discipline.
He also highlights DuPont’s healthy free cash flow, proceeds from the Kevlar transaction, and a new $250 million accelerated share repurchase as evidence that management is actively capitalizing on what it views as an undervalued share price. In addition, DuPont’s exposure to long-term growth themes and the anticipated value creation from the planned Electronics spin-off support the view that the stock can move toward the unchanged $186 price target and outperform its peer group.
In another report released today, UBS also maintained a Buy rating on the stock with a $178.00 price target.
DD’s price has also changed dramatically for the past six months – from $47.830 to $142.930, which is a 198.83% increase.